Overview
- Lilly will build an injectable medicines and device campus in Fogelsville, Upper Macungie Township, to produce Zepbound and, if approved, the experimental retatrutide.
- Construction is slated to begin in 2026 with operations targeted for 2031, supporting about 2,000 construction jobs and creating roughly 850 permanent roles.
- Pennsylvania committed up to $100 million in grants and tax credits plus up to $5 million in RACP funding for workforce training, including a pipeline through Lehigh Carbon Community College.
- The 150-acre site off I-78 was selected from more than 300 proposals for its infrastructure and proximity to STEM universities, and the facility will deploy AI, machine learning and integrated monitoring.
- This marks Lilly’s fourth new U.S. manufacturing site in a recent expansion to strengthen domestic supply of GLP-1 therapies as demand grows and policy pressures encourage onshore production.